You are here: Industry Insights > Opdivo

News List

EC approves Opdivo for treatment of oesophageal squamous cell carcinoma europeanpharmaceuticalreview
November 27, 2020
The European Commission has approved Opdivo (nivolumab) to treat oesophageal squamous cell carcinoma after studies showed its clinical benefits compared to chemotherapy alone.
Bristol Myers Squibb get EC approval for Opdivo (nivolumab) plus Yervoy (ipilimumab) with chemotherapy for metastatic NSCLC expresspharma
November 09, 2020
Opdivo plus Yervoy-based combinations now indicated in the EU for three different advanced cancer types: non-small cell lung cancer, melanoma and renal cell carcinoma.
BMS’ Opdivo combo gets FDA approval for malignant pleural mesothelioma pharmaceutical-technology
October 10, 2020
The US Food and Drug Administration (FDA) has approved Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for treating adults with unresectable malignant pleural mesothelioma (MPM).
Bristol Myers Squibb’s Opdivo shows benefit in oesophageal cancers pharmatimes
September 23, 2020
Bristol Myers Squibb’s Opdivo (nivolumab) demonstrated promise in a phase III CheckMate-577 trial involving patients with oesophageal or gastroesophageal junction (GEJ) cancers who had previously receiving neoadjuvant chemoradiation therapy (CRT) and ...
BMS' Opdivo wins new NICE lung cancer backing pharmatimes
September 21, 2020
NICE has published draft guidance recommending Bristol-Myers Squibb's Opdivo (nivolumab) as a second-line treatment option for patients with squamous or non-squamous non-small-cell lung cancer (NSCLC).
CHMP advises approval for Bristol Myers Squibb’s Opdivo plus Yervoy with chemo for metastatic NSCLC expresspharma
September 21, 2020
The European Commission will now review the CHMP recommendation.
OncoSec Announces Initiation of aStudy to Evaluate Melanoma Treatment americanpharmaceuticalreview
August 31, 2020
OncoSec Medical Incorporated announced the commencement of an investigator-initiated Phase 2 study led by Senior Member and Professor Ahmad A. Tarhini, M.D., Ph.D. of the H. Lee Moffitt Cancer Center and Research Institute and ...
BMS’ Opdivo improves survival in gastric and oesophageal cancers pharmatimes
August 13, 2020
Bristol Myers Squibb has revealed the results from the Phase III CheckMate-649 evaluating Opdivo (nivolumab) plus chemotherapy in first-line metastatic gastric cancer, gastroesophageal junction (GEJ) cancer or oesophageal adenocarcinoma.
Opdivo/Yervoy improves survival in pleural mesothelioma pharmatimes
August 11, 2020
Bristol-Myers Squibb’s immunotherapy combination treatment Opdivo (nivolumab) plus Yervoy (ipilimumab) improved survival in patients with previously untreated, malignant pleural mesothelioma (MPM).
FDA approves Opdivo + Yervoy combined with limited chemotherapy as first-line treatment of metastati pharmaceutical-business-review
May 29, 2020
Bristol Myers Squibb announced that Opdivo (nivolumab) 360 mg plus Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) given with two cycles of platinum-doublet chemotherapy was approved by the U.S. Food and Drug Administration (FDA) ...

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page